Cláudia Marchetti

Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial

Sandro Pignata, Giovanni Scambia, Dionyssios Katsaros et al. · The Lancet Oncology · 2014 · 386 citations

Advanced Ovarian Cancer, Medicine, Metronomic Therapy +7

PI3K/AKT/mTOR Pathway in Ovarian Cancer Treatment: Are We on the Right Track?

Maria Luisa Gasparri, Erlisa Bardhi, Ilary Ruscito et al. · Geburtshilfe und Frauenheilkunde · 2017 · 132 citations · Full text

Mtor Proteins, Gynecology, Cancer Biology +18

Second surgery for recurrent endometriomas is more harmful to healthy ovarian tissue and ovarian reserve than first surgery

Ludovico Muzii, Chiara Achilli, Francesca Lecce et al. · Fertility and Sterility · 2015 · 121 citations

Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome

Sabrina Chiara Cecere, Gaia Giannone, Vanda Salutari et al. · Gynecologic Oncology · 2019 · 103 citations · Full text

Medicine, Cancer Management, Gynecology +9

BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study

Marco Petrillo, Cláudia Marchetti, R. De Leo et al. · American Journal of Obstetrics and Gynecology · 2017 · 92 citations

Cancer Risk, Medicine, Gynecology +8